UPDATE : Monday, September 7, 2020
HOME Special
Korea Biomedical Review’s ‘Top 20’ news
  • By Lee Han-soo
  • Published 2019.12.31 10:17
  • Updated 2019.12.31 10:21
  • comments 0

By most accounts, 2019 was another memorable year for Korea’s medical and biopharmaceutical industries. The nation saw cancer patients rushing to pharmacies to buy Fenbendazole, a dog dewormer, for its alleged efficacy in treating cancer while multinational pharmaceutical companies were engulfed in international conflicts with their labor unions.

This has also been a bountiful year for this newspaper as various news outlets paid increasing attention to the in-depth local news that only Korea Biomedical Review could provide. The paper was cited in major international outlets, including FiercePharma, Endpoints News, The Center For Biosimilar and Business Telegraph.

Some articles that cited the Korea Biomedical Review as its source include “Takeda staffers accuse drugmaker of favoring Shire employees during merger: report (FierecePharma),” “Janssen hands back rights to Hanmi's diabetes/obesity drug (PharmaTimes Online),” “After disappointing investors, SillaJen gets into trouble with Korean prosecutors on suspected insider trading (Endpoints News),” and “Philips, Lunit, Vuno in healthcare AI deal (Healthcare Business News).”

To give our readers a firm grasp of what drew their interests most, Korea Biomedical Review has compiled its top 20 news.

Since every reader has different interests and priorities, however, the selected news might not cover some of our readers’ favorites. If so, please mention which article should have been chosen in the comment section below. – Ed.

1 Dog dewormer gets scarce amid rumors of efficacy in cancer by Lee Han-soo 2019-09-24
2 ‘Invossa, first treatment to have used cancerous cell lines’ by Jeong Sae-im 2019-04-04
3 Conflict erupts between employees of Takeda, Shire during merger by Kim Yun-mi 2019-08-02
4 ‘Fenbendazole has ideal structure as anticancer drug’ by Kim Eun-young 2019-11-12
5 SNUH succeeds in allogeneic hair transplant without immunosuppressant by Lee Han-soo 2019-01-10
6 Interleukin inhibitors Cosentyx, Taltz target psoriasis market by Kim Yun-mi 2019-03-26
7 Breast implant recipients to file class-action suit against Allergan by Song Soo-youn 2019-08-19
8 Hong Waun-ki, renowned cancer researcher, dies at 76 by Lee Han-soo 2019-01-04
9 Korea carries out new plan to end 'healthcare dine and dash' by foreigners by Lee Han-soo 2019-08-09
10 Concerns over TB risk rise amid more use of TNF-α inhibitors by Kim Yun-mi 2019-03-29
11 SillaJen should be ashamed of itself by Jeong Sae-im 2019-08-07
12 PCSK9 inhibitors aim to replace statin in cholesterol reduction by Kim Yun-mi 2019-03-18
13 Female doctors suffer from discrimination at hospitals just because they are 'women' by Song Soo-youn 2019-03-19
14 Patient stabbed doctor to death -- things can’t just go on like this by Song Hyoung-gon 2019-01-03
15 Lilly aims to reshape Korea’s breast cancer treatment market by Lee Han-soo 2019-07-05
16 8 Chinese medical schools delisted from world directory of medical schools by Choi Gwang-seok 2019-11-07
17 Diarrhea drug Smecta banned for children under 2 by Lee Hye-seon 2019-04-24
18 Female doctors suffer discrimination from moment of selecting medical residents by Song Soo-youn 2019-03-15
19 Sanofi Genzyme’s Gaucher disease treatment gets more insurance benefit by Lee Han-soo 2019-03-07
20 Environment against childbirth, rearing causes sexual discrimination by Song Soo-youn 2019-03-20


<© Korea Biomedical Review, All rights reserved.>

Other articles by Lee Han-soo
iconMost viewed
Comments 0
Please leave the first comment.
Back to Top